The PRWIRE Press Releases https:// 2019-11-18T03:48:45Z Aussie medicinal cannabis company, Greenfield MC Global, launches crowd funding campaign offering investment opportunities for under $250 2019-11-18T03:48:45Z aussie-medicinal-cannabis-company-greenfield-mc-global-launches-crowd-funding-campaign-offering-investment-opportunities-for-under-250 Greenfield MC Global, an Australian-owned medicinal cannabis company, has launched an equity crowd-sourced funding (CSF) campaign offering an opportunity for small Australian investors – and first-time investors – to become shareholders in and part-owners of the rapidly growing company. With a minimum investment amount set at just $242, Greenfield MC Global’s CSF has been positioned to make it accessible to people who may not ordinarily consider investing. “In the weeks before launching our CSF, we achieved phenomenal success with our Series B investment round, securing $1.75 million from a wide range of experienced investors, including medical experts, lawyers, high profile business leaders and even celebrities,” explained Nicholas Hanna, CEO of Greenfield MC Global. “With this latest crowd-sourced funding campaign we wanted to open up the opportunity to invest in Greenfield MC Global to the hundreds of smaller investors who reached out to us during our last funding round.” As the number of patients being approved to access medicinal cannabis in Australia continues to soar – with the latest figures showing a 985% increase in approvals from October 2018 to October 2019[1] – Greenfield MC Global will maintain its primary focus on the cultivation, manufacture and distribution of pharmaceutical-grade medicinal cannabis, while also commencing research projects in both New Zealand and the Philippines, and continuing to import high-quality medicinal cannabis for distribution within Australia, from a range of trusted international sources. “We are passionate about the potential of medicinal cannabis to positively impact patients’ lives and we want to ensure that every Australian who needs it, can get it,” said Greenfield MC Global’s Chair and President, Arjun Chhabra. “If the worldwide opioid epidemic has shown us anything, it’s that the status quo approach to patient healthcare, treatment and management needs to change, and we want to be a part of that change. We’re excited to invite Australians who also believe in the power of medicinal cannabis to join us on our mission to revolutionise healthcare in this country.” Greenfield MC Global also welcomed the new Parliamentary Inquiry into the accessibility and regulation of medicinal cannabis in Australia announced last week, with Chief Operations Officer Katy Williams Day adding, “We look forward to the findings of the Senate’s Community Affairs Committee from the Parliamentary Inquiry next February with great anticipation. Improving the accessibility and affordability of medicinal cannabis for Australians is a key priority for Greenfield MC Global and we hope that this Inquiry accurately identifies the existing barriers and outlines ways to effectively reform the system.” Greenfield MC Global’s CSF is offered via Capital Labs, the equity CSF platform of The iQ Group Global, and one of the first equity CSF platforms to be approved by ASIC. The CSF is open now and will close on 12 December 2019 capitallabs.com/greenfieldmc Medicinal Cannabis – Key Facts The global medicinal cannabis industry is predicted to be worth US$150bn by 2025[2] The medicinal cannabis market in APAC is expected to tip USD$5.8bn by 2024[3]. More than 3,500 approvals for medicinal cannabis were issued in Australia via the Special Access Scheme in October 2019, an increase of 985% in 12 months[4] Up to 20,000 new patients are expected to enter the medicinal cannabis market in Australia over the next 12 months[5] A new Federal Parliamentary Inquiry into the accessibility and regulation of medicinal cannabis in Australia was announced on 14 November 2019, with the report due in February 2020 Legislation was amended to allow research into and cultivation of cannabis for medicinal use in Australia in 2016 Medicinal cannabis is currently approved for use in 42 different health conditions in Australia, including some forms of epilepsy, some cancers and side-effects of cancer, chronic pain, inflammatory conditions, neurological conditions and more. – ENDS – Distributed by Uproar Marketing on behalf of Greenfield MC Global Media contact: Rachel McDougall | rachel@uproarmarketing.com.au | 0401 694 301 NOTES FOR EDITORS Images and Video Resources A collection of high-resolution images, including photographs of Greenfield MC Global CEO Nicholas Hanna visiting Canadian cannabis producer EPHS Holdings’ cultivation site 43 second promo video – featuring Dr Ben Barresi and Arjun Chhabra About Greenfield MC Global Greenfield MC Global is a licenced medicinal cannabis importer and distributor in Australia, with expanding operations in cultivation, research and distribution in the Asia-Pacific region. Independent and privately owned, Greenfield MC Global focuses on medicine, science and results. Formed in 2018, Greenfield MC has a vision to be Asia-Pacific’s leading wholesaler and patient-retailer of medicinal cannabis products. Headquartered in Sydney, Australia, Greenfield MC Global is also represented across Melbourne and Brisbane in Australia, as well as New Zealand, South Korea and the Philippines. For further information visit: www.greenfieldmc.com.au About Capital Labs Capital Labs is an equity crowd-funding platform dedicated to launching innovations with impact. Partnering only with companies launching technology and innovations that have a positive influence on the world, Capital Labs enables early stage companies and start-ups to raise capital from investors in exchange for shares in their business. Capital Labs is powered by The iQ Group Global, a group of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations. For further information visit: https://capitallabs.com and www.theiqgroupglobal.com. [1] Fresh Leaf Analytics Oct 2019 [2] Grandview Research 2018 [3] Prohibition Partners, The Asian Cannabis Report, May 2019 [4] Fresh Leaf Analytics Oct 2019 [5] Fresh Leaf Analytics: Patient, Product and Pricing Analysis Q1 2019 Australia’s Greenfield MC announces NZ-based Joint Venture to cultivate and research medicinal cannabis 2019-09-06T02:25:20Z australias-greenfield-mc-announces-nz-based-joint-venture-to-cultivate-and-research-medicinal-cannabis-3 The Joint Venture will see Greenfield MC become the first Australianowned company to set up operations to cultivate medicinal cannabis for research purposes in New Zealand. An objective of the JV is to research the safety and efficacy of medicinal cannabis for the treatment of health conditions disproportionately affecting Maori. Greenfield MC, an Australian-owned medicinal cannabis company, has announced a Joint Venture (JV) with Canada’s EPHS Holdings Inc. (STNN:US), a US-listed commercial cannabis producer and New Zealand-based Wepiha Health Co to cultivate medicinal cannabis in New Zealand for research purposes. The JV, to be known as Greenfield MC Limited (NZ), is the first Australian-owned operation to focus on cultivating medicinal cannabis for research purposes in New Zealand. The JV’s initial research project will study the efficacy of growing specific strains of the cannabis plant in various environments in New Zealand, with future research projects likely aiming to examine the effectiveness and safety of medicinal cannabis for certain health conditions that disproportionately affect Maori, such as Type 2 Diabetes Mellitus (T2DM).[1] Greenfield MC and EPHS’ strategic partnership with Wepiha Health Co will ensure that any research projects studying Maori health will be conducted within a Kaupapa Maori framework– that is, a project conducted by Maori, for Maori and with Maori. “In New Zealand, health disparity for Maori is a key area of focus,” explained Greenfield MC Limited (NZ)’s Director of Research, Dr Anna Rolleston, “with disparities in almost all areas of health attributed largely to system-related issues and social determinants of health. Once we have cultivation underway in New Zealand and have completed our initial research project, one of the objectives is to understand how medicinal cannabis could be beneficial to Maori healthcare and how the industry as a whole might support Maori aspirations.” Forming the Greenfield MC Limited (NZ) team are Dr Anna Rolleston as Director of Research, Mariana Hudson as Chief Pharmaceutical Officer and Hans Dirkse as an Advisory Board Member. The company is also consulting with a lead clinical trialist and biostatistician who will support the development of the research project protocol. Dr Anna Rolleston is a Senior Research Fellow at both the University of Auckland and the University of Waikato, and a Director at The Centre for Health Ltd. She specialises in Kaupapa Maori health research, with an emphasis on chronic disease. Mariana Hudson is a Pharmacist who is the Director of Apothecary Limited and the current Vice President of The Maori Pharmacists’ Association, and Hans Dirkse was the inaugural Chair of the Certified Organic Kiwifruit Association and is a leader in organic grow operations who has spent a lifetime working in the agricultural sector. “We are very proud of the New Zealand-based team we have assembled,” said Greenfield MC’s Chief Medical Officer Dr Sree Appu. “They have outstanding experience in their fields of expertise and have an intimate understanding of what is required to ensure that any research projects we conduct are culturally sensitive, empowering and further the case for medicinal cannabis as a form of treatment.” Greenfield MC Limited (NZ)’s New Zealand cultivation operation is anticipated to commence by Q2 2020, with the research projects to commence after the first harvest. The company is working towards lodging its NZ medicinal cannabis licence to cultivate for research and will ultimately look to include NZ importation and distribution licences. “We are passionate about the potential of medicinal cannabis to positively impact patients’ lives,” concluded Nicholas Hanna, Greenfield MC’s CEO, “and we believe that this new Joint Venture in New Zealand will take us one step closer to becoming a leading producer and supplier of medicinal cannabis products in the Asia-Pacific and Oceania regions.” - ENDS - Distributed by Uproar Marketing on behalf of Greenfield MC Media contact: Rachel McDougall | 0401 694 301 | rachel@uproarmarketing.com.au Notes for Editors About Greenfield MC Greenfield MC is a licenced medicinal cannabis importer and distributor in Australia, with expanding operations in cultivation, research and distribution in the Asia-Pacific region. Independent and privately owned, Greenfield MC focuses on medicine, science and results. Formed in 2018, Greenfield MC has a vision to be Asia-Pacific’s leading wholesaler and patient-retailer of medicinal cannabis products. Headquartered in Sydney, Australia, Greenfield MC is also represented across Melbourne and Brisbane in Australia, as well as New Zealand, South Korea and the Philippines. For further information visit www.greenfieldmc.com.au About EPHS Holdings Inc. (STNN:US) EPHS Holdings Inc. is a licensed commercial cannabis cultivator engaging in the cultivation, possession, research, processing, sales, and distribution of medicinal and recreational cannabis under the licensing regime of a Health Canada Licensed Producer. EPHS has an existing grow operation in Montreal and is constructing a second grow operation in Merritt BC, which should scale up to 1.2 million square feet of cultivating greenhouses. EPHS is committed to delivering premium medical cannabis using fully integrated purpose built, intelligently controlled buildings coupled with environmentally friendly low-cost energy and micro grid systems. For further information visit www.ephsholdings.com About Wepiha Health Co. Wepiha Health Co is a newly created entity led by Maori clinical researchers and academics, agriculturalists, and leading pharmacists. Its founders include Dr Anna Rolleston, a Senior Research Fellow at both the University of Auckland and the University of Waikato, and a Director at The Centre for Health Ltd, and Rush Wepiha, who is an internationally recognised indigenous youth mentor and speaker who focuses his platform on the development of better healthcare and medical education in rural and/or Maori communities. [1] Prevalence of T2DM among Maori is estimated to be about twice that of non-Maori https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/diabetes Greenfield MC announces Joint Venture with Canadian licensed producer EPHS Holdings Inc to cultivate medicinal cannabis in Australia 2019-08-06T01:30:00Z greenfield-mc-announces-joint-venture-with-canadian-licensed-producer-ephs-holdings-inc-to-cultivate-medicinal-cannabis-in-australia Media Release Greenfield MC announces Joint Venture with Canadian licensed producer EPHS Holdings Inc. to cultivate medicinal cannabis in Australia The Joint Venture will see Greenfield MC add cultivation of medicinal cannabis to its existing import and distribution activities Greenfield MC will launch a Series B investment round in late Q3 2019 Greenfield MC, a rising player in the Australian medicinal cannabis market and EPHS Holdings Inc. (STNN:US), a US-listed commercial cannabis producer with grow operations in Canada, have announced a joint venture to cultivate medicinal cannabis in Australia. The joint venture will be oriented towards exporting to Asia, which is expected to become the world’s largest patient and consumer market for medicinal cannabis. The joint venture will combine Greenfield MC’s local and international medical and pharmaceutical expertise with EPHS’s many years of experience and proven track record in commercial cannabis cultivation. EPHS has been growing medical-grade cannabis for several years and has been approved as a Health Canada Licensed Producer since 2013. “EPHS has the kind of in-depth knowledge and track record that will assist us to quickly establish ourselves as leading cultivators here in Australia,” says Greenfield MC CEO Nicholas Hanna. “They have expertise in establishing state-of-the-art cultivation facilities, IP and genetics, and numerous strategic global partnerships. That leverage will allow Greenfield MC to hit the ground running when it comes to Australian cultivation. With EPHS at the helm, there will be no need to re-invent the wheel or learn on the job, and we can avoid teething and execution issues.” “This joint venture with Greenfield MC has come at just the right time for us,” explains Stevan Perry, President of EPHS. “EPHS is a leader in the North American cultivation space. Our plan is to take our years of commercial experience, expertise and know-how into the global marketplace to cater to what promises to be a wave of industry development across Australia and the Asia-Pacific, capitalising on projected consumer numbers growth, and increasing regulatory awareness of the healthcare benefits of this new pharmaceutical product category. We have been looking for a medicinal cannabis company in Australia to partner with that shares our vision of providing high-quality low-cost medicinal cannabis, and we’re excited to have found it in Greenfield MC. Through our joint venture, we are perfectly positioned to open up these new markets.” Cultivation under the joint venture is expected to commence in late-2020. Locations are currently being scouted for establishment of the cultivation facility, with Queensland’s Sunshine Coast of particular interest due to its favourable climate and natural light-cycle. Continues Hanna, “We are very proud to partner with such a well-respected organisation in the global cannabis space and believe this partnership will bring to market Australian-grown medicinal cannabis products for hundreds of thousands of Australian patients with a wide range of health conditions.” “Australia’s reputation for best agricultural practices, crop safety management systems and robust quality control will make Australian-grown cannabis the envy of the global market and provide patients with confidence in this new form of medical treatment”, explains Kevin Smith, EPHS’s Vice President for Strategy and Business Development. “For those very reasons, we see Australia as the gateway to Asia, which it already is in various agricultural and pharmaceutical product categories.” Members of the EPHS team will relocate to Australia to assist with the establishment and operation of the local cultivation facility. The EPHS team will look to replicate its proven high yield low cost energy production methods to deliver premium quality medicinal cannabis to Asia-Pacific markets. “It’s extremely important to us at EPHS to integrate ourselves into each community that we operate in,” adds Perry. “Our joint venture with Greenfield MC will see us share our many years of experience in cultivation with the team on the ground in Australia, helping them to avoid the many traps and pitfalls that new cultivators can often face. We hope to be Australia’s and the Asia-Pacific’s trusted supplier of medicinal cannabis crops and products.” The joint venture marks a key milestone in Greenfield MC’s plan to become a leading producer and supplier of medicinal cannabis products in the Asia-Pacific and Oceania regions. Greenfield MC will launch a Series B investment round in late Q3 2019. - ENDS- Distributed by Uproar Marketing on behalf of Greenfield MC. Media contact: Rachel McDougall | 0401 694 301 | rachel@uproarmarketing.com.au See Previous Announcement: Australian Medicinal Cannabis Startup Secures Leading Oncologist as CMO About Greenfield MC Greenfield MC is a licenced medicinal cannabis importer and distributor in Australia, with expanding operations in cultivation, research and distribution in the Asia-Pacific region. Independent and privately owned, Greenfield MC focuses on medicine, science and results. Formed in 2018, Greenfield MC has a vision to be Asia-Pacific’s leading wholesaler and patient-retailer of medicinal cannabis products. Headquartered in Sydney, Australia, Greenfield MC is also represented across Melbourne and Brisbane in Australia, as well as New Zealand, South Korea and the Philippines. For further information visit www.greenfieldmc.com.au About EPHS Holdings Inc. (STNN:US) EPHS Holdings Inc. is a licensed commercial cannabis cultivator engaging in the cultivation, possession, research, processing, sales, and distribution of medicinal and recreational cannabis under the licensing regime of a Health Canada Licensed Producer. EPHS has an existing grow operation in Montreal and is constructing a second grow operation in Merritt BC, which should scale up to 1.2 million square feet (28 acres) of cultivating greenhouses. EPHS is committed to delivering premium medical cannabis using fully integrated purpose built, intelligently controlled buildings coupled with environmentally friendly low-cost energy and micro grid systems. For further information visit www.ephsholdings.com Australian medicinal cannabis startup secures leading oncologist as CMO 2019-08-01T00:13:30Z australian-medicinal-cannabis-startup-secures-leading-oncologist-as-cmo Media ReleaseInnovative Australian Medicinal Cannabis startup secures high profile leaders from Medical and Pharmaceutical industries An emerging player in the Australian medicinal cannabis market, Greenfield MC, has established a team of leaders from the medical and pharmaceutical worlds, securing the expertise of world-renowned oncologist Dr Sree Appu and high-profile sports doctor Dr Ben Barresi, alongside former pharmaceutical senior executives, including Katy Williams Day. Dr Appu, a leading figure in clinical oncology and the recent Clinical Head of Urology at Monash Cancer Centre, brings many years of experience to Greenfield MC in his role as Chief Medical Officer. Dr Appu has been avidly following the growing body of research in the medicinal cannabis area and is excited to have a leading role in what comes next. “It’s an emerging market with numerous opportunities, and now that medicinal cannabis is available for both research and clinical purposes here in Australia, we are seeing it lose some of the stigma and being recognised as a form of treatment in cancer management, palliative care and other areas,” explains Dr Appu, who is also Chairman of Greenfield MC’s Medical Board. “At Greenfield MC, we are in a unique position to conduct ethical and clinically based research on the therapeutic benefits of medicinal cannabis as well as provide affordable access for patients. We are doing so backed by a team of highly experienced medical professionals, pharmacists, former pharmaceutical executives and lawyers who have the ability to develop the best therapeutic options based on clinical research, who understand the intricacies of bringing a new drug to market, and can engage in market research product development.” Dr Ben Barresi, a GP with special interests in sports, occupational and addiction medicine who also sits on Greenfield MC’s Medical Board, agrees, adding, “Greenfield MC has assembled a team of highly regarded and well-respected health professionals from a variety of medical and allied health disciplines. I believe their knowledge, experience and ability to interpret the medical literature, as well as their intimate understanding of the healthcare system, will be of enormous benefit in helping patients to access effective medicinal cannabis treatment options.” Dr Barresi, who has held key positions in the AFL as a team doctor, primarily with Carlton Football Club, has seen many patients benefit from the use of medicinal cannabis, including for pain relief and management of mental health conditions, and is eager to improve the way treating doctors and health providers are able to access medicinal cannabis for their patients. Other members of the Greenfield MC Medical Board include Neurologist Prof. Robert Iansek OAM, Psychiatrist A/Prof Ajeet Singh and ICU Specialist and Anaesthetist Dr Dharshi Karalapillai. From the pharmaceutical industry comes Katy Williams Day, who is leading Greenfield MC as Chief Operating Officer. Day has previously worked at Pfizer, Genzyme, Sanofi and Merck in various senior leadership roles, as well as an ASX-listed medicinal cannabis company. As a pharmacist, her background spans more than 20 years in the medical and pharmaceutical industries. She has extensive experience in compliance, regulatory affairs and new product introduction, as well as an in-depth understanding of the TGA. She has strong links with the medicinal cannabis industry in Australia and overseas and has witnessed the many benefits of its uses through her work with a range of patient advocacy groups. “The key advantages of medicinal cannabis, from what has been demonstrated so far, are the positive benefits for patients with unmet medical needs or where standard regimens have not provided patients with a successful outcome”,” says Day. “Coming from a pharmaceutical background, we believe that focusing on providing affordable access to medicinal cannabis, supporting education programs and ongoing research and development efforts are the areas where Greenfield MC has the experience and most potential to help patients in need. We want to make sure that every Australian who needs medicinal cannabis can access and afford it.” Day believes that being able to navigate the complex Australian regulatory system will set Greenfield MC apart. “There are a lot of barriers to the industry when you’re supplying medicines, and the approvals process is the biggest barrier of all,” she explains. “Our team has decades of experience working through regulatory approval systems, which gives us an advantage.” Others joining with pharmaceutical industry backgrounds include: Tony George, Greenfield MC’s Financial Officer, who was Head of Finance Operations at Pfizer across Australia and New Zealand for close to 20 years; Meilani Humphreys, who brings vast expertise in launching new pharmaceutical products; and Sandip Manku, a registered Pharmacist of more than 20 years’ experience and founder of a specialist pharmaceutical wholesaler and importer. Janja Jelic, also a Pharmacist, joins Greenfield MC as head of Patient and Doctor Relations; she has seen first-hand the benefits that medicinal cannabis can bring to people with chronic conditions, after a close family member with terminal cancer was prescribed medicinal cannabis to help with chemo-related nausea and vomiting. “It took a while for her to get access through the right channels,” explains Jelic, “but once her specialist prescribed medicinal cannabis oil, it made a positive difference to her quality of life over those final months.” Jelic is passionate about ensuring all medicinal cannabis products supplied to the Australian market are carefully regulated, approved and administered. She will also be heavily involved in GP education, liaising with doctors to help them understand the benefits medicinal cannabis can bring to patients. This breadth of medical and pharmaceutical knowledge has been brought together by the co-founders of Greenfield MC, Nicholas Hanna, CEO, and Arjun Chhabra, Chairman and President, both lawyers with experience across regulatory, drug and health law. “Our aim is to be a leading producer and supplier of quality medicinal cannabis products in the Asia-Pacific region,” says Chhabra. “We purposefully set out to form a team with strong medical and pharmaceutical backgrounds. Their knowledge and expertise, combined with our joint ventures with global partners, mean we are poised to achieve vertical integration with low-cost cultivation and sophisticated distribution networks across multiple countries.” Adds Day, “It’s all about providing greater access and more affordable healthcare to patients. We all started working in the medical and pharmaceutical industries because we wanted to help people, to have a hand in improving health outcomes and changing lives. We see medicinal cannabis as another avenue to offer people who have exhausted other treatment options, and we want to make sure that the products available to Australians are of the highest quality and lowest cost.” “Access, affordability and quality – that’s what Greenfield MC is all about,” finishes Dr Appu. Greenfield MC will be launching a Series B investment round in late Q3 2019. More information can be found at www.greenfieldmc.com.au. - ENDS –Distributed by Uproar Marketing on behalf of Greenfield MC.Media contact: Rachel McDougall | 0401 694 301 | rachel@uproarmarketing.com.au  Notes for EditorsAbout Greenfield MC Greenfield MC is a licenced medicinal cannabis importer and distributor in Australia, with expanding operations in cultivation, research and distribution in the Asia-Pacific region. Independent and privately owned, Greenfield MC focuses on medicine, science and results. Formed in 2018, Greenfield MC has a vision to be Asia-Pacific’s leading wholesaler and patient-retailer of medicinal cannabis products. Headquartered in Sydney, Australia, Greenfield MC is also represented across Melbourne and Brisbane in Australia, as well as New Zealand, South Korea and the Philippines. For further information visit www.greenfieldmc.com.auMedicinal Cannabis in Australia Australian Parliament passed legislation in February 2016 to enable the cultivation of cannabis for medicinal and scientific use through a licensing scheme to be established under the Narcotic Drugs Act 1967. Medicinal cannabis was first legalised in Australia on 30 October 2016; however, the market is tightly regulated by the Federal Government office of Drug Control. In 2017, the TGA rescheduled some medicinal cannabis products to Schedule 8 of the Poisons Standard, making the prescription of medicinal cannabis in Australia legal. The Australian medicinal cannabis industry has been projected to be worth $12.3 billion by 2028. Medicinal cannabis is currently available to patients in Australia through: Authorised Prescriber Scheme (AP) Special Access Scheme (SAS) Clinical trials Prescribers must have considered all clinically appropriate treatment options included in the Australian Register of Therapeutic Goods (ARTG) before prescribing unapproved medicinal cannabis products. As of June 2019, there are 56 Authorised Prescribers in Australia. Up to 30 June 2019 there had been 9,300 approved applications through the Special Access Scheme for unapproved medicinal cannabis products. TGA has approved applications including, but not limited to: chemotherapy-induced nausea and vomiting refractory paediatric epilepsy palliative care indications cancer pain neuropathic pain spasticity from neurological conditions anorexia and wasting associated with chronic illness (such as cancer). Prohibition Partners Oceania Cannabis Report 2018